INCB 54329

Drug Profile

INCB 54329

Alternative Names: INCB-054329; INCB-54329

Latest Information Update: 05 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action BRD2-protein-inhibitors; BRD3 protein inhibitors; BRD4-protein-inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies; Solid tumours
  • Preclinical Pancreatic cancer; Prostate cancer

Most Recent Events

  • 02 Apr 2017 Pharmacodynamics data from a preclinical trial in Diffuse large B-cell lymphoma presented at the 108th Annual Meeting of the American Association for Cancer Research(AACR-2017)
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Pancreatic cancer presented at the 108th Annual meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Apr 2017 Preclinical trials in Pancreatic cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top